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Abstract
Background: Chronic pancreatitis presents a high risk of inflammation-related progression to pancreatic cancer.
Pancreatic cancer is the fourth leading cause of cancer-related death worldwide. The high mortality rate is directly
related to the difficulty in promptly diagnosing the disease, which often presents as overt and advanced. Hence,
early diagnosis for pancreatic cancer becomes crucial, propelling research into the molecular and epigenetic
landscape of the disease.
Main body: Recent studies have shown that cell-free DNA methylation profiles from inflammatory diseases or
cancer can vary, thus opening a new venue for the development of biomarkers for early diagnosis. In particular,
cell-free DNA methylation could be employed in the identification of pre-neoplastic signatures in individuals with
suspected pancreatic conditions, representing a specific and non-invasive method of early diagnosis of pancreatic
cancer. In this review, we describe the molecular determinants of pancreatic cancer and how these are related to
chronic pancreatitis. We will then present an overview of differential methylated genes in the two conditions,
highlighting their diagnostic or prognostic potential.
Conclusion: Exploiting the relation between abnormally methylated cell-free DNA and pre-neoplastic lesions or
chronic pancreatitis may become a game-changing approach for the development of tools for the early diagnosis
of pancreatic cancer.
Keywords: Chronic pancreatitis, Pancreatic cancer, Cell-free DNA, DNA methylation, Diagnostic methods, Pre-
neoplastic lesions
Background
Chronic pancreatitis (CP) represents a spectrum of per-
sisting fibro-inflammatory disorders of the exocrine pan-
creas that alter the organ’s typical structure and
functions, and significantly reduce patients’ quality of life
[1]. Genetic predisposition [2, 3], neoplasms, intraductal
obstruction, or autoimmune pancreatitis (AIP) can all
cause CP [4]. Alcohol history is considered a significant
risk factor, and tobacco smoking may act synergistically
with alcohol [5]. CP affects ∼ 50 per 100,000 individuals
worldwide, with an incidence that is expected to increase
over time [5]. The disease often presents with upper
abdominal pain, nausea or vomiting, and steatorrhea.
The diagnosis is based on tests on pancreatic function
or structure, such as elevated amylase or lipase serum
levels, secretin stimulation, or computed tomography.
The persistent inflammatory state in CP promotes
accelerated tissue repair, which may result in neoplastic
(trans)formation. For this reason, CP represents one of
the highest risk factors for the development of pancre-
atic tumors (PTs) [6, 7]. PT is an aggressive disease usu-
ally asymptomatic at an early stage displaying symptoms
resembling CP once it is overt [8]. This feature hinders
early diagnosis, contributing to high observed mortality
(5-year survival: ∼ 6%) [9, 10]. The global incidence rate
of PT in 2012 was about six per 100,000 individuals [9]
and, coherently with CP, it is expected to increase over
time.
In the absence of an underlying PT, the lag period be-
tween CP diagnosis and tumor is usually one or two
decades [11, 12]. This long latency period might offer a
strategic opportunity for early diagnosis and curative
treatment once biomarkers with robust predictive power
are discovered.
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The best-known biomarker for PT is the serum protein-
carbohydrate antigen 19-9 (CA19-9, or sialylated Lewis
antigen) [13]. When released by a PT, CA19-9 levels can
help to monitor the treatment or the relapse of the disease
[14]. Unfortunately, elevated CA19-9 levels are also
present in CP or other cancers [15]. Besides, about 10% of
the Caucasian population lacks CA19-9 on their red blood
cells [15]. Due to these limitations, the American Society
of Clinical Oncology discouraged the use of CA19-9 as a
biomarker for PT diagnosis [14]. The lack of robust non-
invasive diagnostic screening methods has propelled the
research of potential biomarkers in patients’ biological
fluids. Sequence analysis of cell-free DNA (cfDNA) from
the bloodstream of patients affected by PT uncovered mu-
tations in the KRAS already in the early 90s [16], and im-
provement of these methods was attained in the past years
[2, 17]. A more recent and emerging field investigates the
methylation levels of circulating cfDNA. This approach is
actively used for the discovery of biomarkers of several
diseases [18–20]. Its popularity stems from the increasing
evidence that cfDNA carries methylation marks that en-
able the identification of tissue-specific cell death [21] and
are more broadly informative, sensitive, and specific than
individual DNA mutations [22–24]. Further, sample col-
lection is minimally invasive and allows adequate follow-
up under negligible stress conditions for the patient.
In this review, we provide an overview of the molecu-
lar determinants of PT and the genes showing differen-
tial DNA methylation in CP, pre-neoplastic lesions of
the pancreas, and PT. In particular, we will compare
studies conducted either on primary tissue biopsies or
from biological fluids. We aim to decipher disease-spe-
cific methylation patterns in pancreatic diseases to serve
as a novel diagnostic or prognostic tool for PT. The
identification of a “pancreatic disease signature” to dis-
tinguish between inflammation and cancer could hope-
fully enhance non-invasive tools for the early diagnosis
of PTs.
The molecular landscape of pancreatic cancer and
pancreatitis
The pancreatic adenocarcinoma develops almost exclu-
sively from the exocrine pancreatic ductal epithelium
cells accounting for 85% of all PTs. Other PTs include
the acinar cell carcinoma originating from the exocrine
acini of the pancreas, the pancreatic neuroendocrine tu-
mors (PNETs) arising from neuroendocrine cells, and
other minorities. For its abundance, we will hereafter
use the term PT to refer to pancreatic ductal adenocar-
cinoma, unless otherwise specified.
Molecularly, a variety of genetic and epigenetic events
underlie the development of PT (Fig. 1).
Pre-neoplastic non-invasive lesions are thought to be
the first stage of PT etiopathogenesis. Low-grade pancre-
atic intraepithelial neoplasia (PIN) is the most frequent
microscopic lesion of the pancreas, harboring mutations
in the KRAS in about 90% of the cases [8, 32]. As the
grade of the lesion progresses, additional mutations in
Fig. 1 Genetic landscape of pancreatic cancer. Genes mutated in pancreatic ductal adenocarcinoma (PT, top) and pancreatic neuroendocrine
tumor (PNET, bottom). For the former, genetic predisposition or copy number alterations are also reported (reviewed in [25]). At the pre-
neoplastic stage (dotted line), pancreatic intraepithelial neoplasias (PIN) and intraductal papillary mucinous neoplasms (IPMN) coexist. Overall,
aberrant homeostasis of genes regulating cell differentiation, proliferation and apoptosis promote the transition from pre-neoplastic to advanced
stages of the disease [26–31]. Chronic pancreatitis (CP) may also be present, contributing to the progression of an underlying tumor
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cell cycle-regulating CDKN2A and TP53 are found [8].
Intraductal papillary mucinous neoplasms (IPMNs) are
macroscopic lesions and have a 25% risk of developing
into invasive PT. Other than KRAS, they often present
mutations in genes involved in the Wnt signalling path-
way (e.g., GNAS and RNF43) [8]. Other types of lesions
include mucinous cystic neoplasms and intraductal
tubulopapillary neoplasms [32, 33].
Genes mutated in PNETs are generally different from
those found in exocrine PTs [34]. For example, KRAS
mutation is absent in most PNETs, while frequent muta-
tions in these tumors occur in DAXX (encoding the
transcriptional corepressor death domain-associated
protein 6), MTOR (encoding the mammalian target of
rapamycin kinase), and MEN1 genes [35].
At the invasive stage, PTs present mutations in
SMAD4 (about 55% of the cases) and genes of the SWI/
SNF chromatin remodeling family (∼ 15% of the cases)
[6, 8]. A member of this family, ATRX, is frequently mu-
tated in PNETs [35], and these events have been shown
to cause changes in DNA methylation patterns [36, 37].
The latter, together with aberrant DNA hydroxymethyla-
tion, are established processes contributing to cancer de-
velopment [38–41].
Inflammatory stimuli may lead to aberrant DNA
methylation homeostasis and, coherently, to gene ex-
pression changes [39, 42–44]. Further, the progressive
increase of DNA methylation levels has been described
in chronic inflammatory diseases developing into cancer.
The interactions between inflammation and epigenetics
in tumor initiation, promotion, and immune evasion can
be leveraged in cancer prevention and treatment [40].
Thus, it is not surprising that the relative risk for CP
patients developing PT is generally > 10 [11, 45]. In this
scenario, chronic inflammation may inactivate the onco-
gene-induced senescence barrier that is typical for pre-
neoplastic PIN lesions and, thus, it promotes the neo-
plastic progression of PT [46]. Genetically, 4–28% of CP
cases show KRAS mutation [2, 3].
Conversely, no KRAS mutation at known tumor-pro-
moting sites has so far been observed in AIP [47]. Fi-
nally, the mutation of the STK11, a known risk factor for
PTs, has recently been described in CP [17]. In the past
two decades, a significant number of studies conducted
in pancreatic cell lines, xenografts, or primary tissue speci-
mens aimed at identifying aberrant DNA hyper- or hypo-
methylation targets in PTs. Almost all DNA methylation
analyses rely on PCR-based methods, on bisulfite-
treated—or not—specimens [48]. For their high through-
put, microarray or—more recently—next-generation
sequencing (NGS) methods enabled the discovery of many
target genes. The fast and cost-containing methylation-
specific PCR (MSP) is generally the method of choice for
target validation. This approach led to the identification of
many candidate genes associated with epigenetic changes
taking place during the carcinogenesis of PT. In this sec-
tion, we will discuss those genes whose DNA methylation
levels hold potential for the differential diagnosis of CP,
pre-neoplastic conditions of the pancreas, and invasive
PTs. Besides, the genes, as well as the method employed
for their discovery and validation, will be described.
Differentially DNA-methylated genes in pancreatic
tumor and pancreatitis
The first studies comparing cancerous and healthy
pancreatic tissues analyzed the methylated status of
known tumor-suppressors and cancer-associated genes.
Also, specific CpG islands spread within the genome were
found preferentially methylated in tumors (MINT loci). In
particular, the DNA methylation status of CpG islands
embedded in several gene promoters (CACNA1G, CDH1,
CDKN2A, DAPK1, MGMT, MINT1-2-31-32, MLH1,
RARB, THBS1, and TIMP3) was analyzed in PT xenografts
[49, 50]. All cancerous specimens showed aberrant DNA
methylation of at least one locus except forMGMT, which
was non-methylated in either neoplastic or normal sam-
ples. Simultaneous methylation of at least four loci was a
feature of ∼ 14% of PT xenografts. Overall, the most fre-
quently methylated loci were MINT32, MINT1, and
MINT28. Moreover, seven CpG islands (CGIs), of which
three associated to the known CCNG1, PENK, ZBP genes,
were found differentially methylated in pancreatic-derived
cell lines compared with the healthy pancreas and vali-
dated in PTs [51, 52]. Among these PENK, CGI was found
methylated in 91% of cases. Of note, five specimens of CP
were also analyzed, showing PENK CGI methylation in
two cases [52].
PENK, as well as CDKN2A, DNA methylation status
was further investigated in PINs of different grade:
intraductal PTs, extra-ductal PTs (including one
PNET), and CP specimens [53, 54]. PENK methylation
was present in 93% of invasive PTs, of which 27% pre-
sented CDKN2A methylated. In contrast, non-neoplas-
tic specimens resected from matched healthy tissues
did not harbor methylation of either gene. Noteworthy,
the prevalence of PENK methylation increased signifi-
cantly with increasing lesion grade (from 8 to 46%, in
grade 1A or grade 3 lesions, respectively). Only one of
the extra-ductal PTs presented CDKN2A methylation,
while CP specimens had neither gene methylated. Inter-
estingly, as regarding CDKN2A, available data suggest
that hypermethylation associated with the loss of
CDKN2A expression might occur only in CP in which
low-grade PINs were observed [45]. In line with its
broad role as a tumor suppressor, the downregulation
of CDKN2A expression was found in this study inde-
pendently of methylation status.
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These data support the disease stage-specific DNA
methylation model and qualify these genes as potential
biomarkers of early pancreatic carcinogenesis.
Comparing invasive PTs to IPMNs, 6% of IPMNs
and 22% of invasive PTs presented SOCS1 methyla-
tion. In contrast, none of the pancreatic normal
ductal epithelia and the PINs that were analyzed pre-
sented SOCS1 methylation [55]. In a preliminary
study, the analysis of IPMNs with different grades of
invasiveness reported SOCS1 methylation in 6% of in-
vasive IPMNs [56], providing evidence that, therefore,
this gene might be an early indicator of invasiveness
of the disease. About half of the tested specimens
scored positive for CDKN2A (p16INK4a specific re-
gion) and TP73 methylation, independently of their
grade of invasiveness. Conversely, CDKN2B, ESR1,
and TIMP3 were methylated in none of the examined
specimens. More frequent methylation of APC (50%
vs. 10%), CDH1 (38% vs. 10%), MGMT (45% vs. 20%), and
MLH1 (38% vs. 10%) was observed in invasive IPMNs,
compared to non-invasive samples. Unfortunately, the
weakness of these findings results from the limiting size of
the non-invasive IPMN subpopulations [45].
A progressive increase of the DNA methylation of at
least one gene and the average number of methylated
genes was observed from PIN to PT in 58 patients who
had undergone resection surgery for invasive PTs.
The impact of the inflammatory environment on DNA
methylation was assessed. The data showed that DNA
methylation also increases with inflammation of pancre-
atic tissue. BRCA1, APC, CDKN2A, and TIMP3 were
methylated in 60%, 59%, 39%, and 31% of the PT cases,
respectively [57]. Finally, the DNA methylation levels of
six genes frequently hypermethylated in PT (CCND2,
CDKN2A, FOXE1, NPTX2, PENK, TFPI2) were analyzed
in AIP specimens [47], showing no significant hyperme-
thylation in both AIP or healthy pancreas.
Evidence of DNA hypomethylation events in PTs is
also reported [58–60]. A panel including 18 genes
known to be over-expressed in PTs and 14 genes whose
overexpression in PT was not documented was com-
posed. MSP analysis revealed methylation of 19 of 32
genes in healthy pancreas. All genes that were known to
be transcribed at high levels in PTs but not expressed in
healthy pancreas (CLDN4, LCN2, MSLN, PSCA, S100A4,
TFF2, and YWHAS) were frequently hypomethylated in
PT xenografts. In particular, five or six genes showed
simultaneous DNA hypomethylation in 92% or 61% of
the cases, respectively. Moreover, from 379 identified
loci hypomethylated in PT with respect to healthy pan-
creas [61], the oncogenes FOS, JUNB, and MYB; the
genes NDN and SMARCA1 [62]; and the chromatin
modifiers genes such as CTR9, EP400, HIRIP3, KDM6A,
KMT5A, and PRMT1 were identified. These genes
presented increased expression in PT specimens playing
a role in core signalling pathways of PT [60].
In Additional file 1: Table S1, we reported a list of
several studies that analysed the methylation status of
different genes. Genes, commonly addressed in both
primary tissues and liquid biopsies (see next section),
were grouped and highlighted in gray.
Genome-wide profiling of methylated genes in pancreatic
tumor and pancreatitis
The advent of genomic technologies improved the
screening capability by several orders of magnitude, pro-
viding promising results. Using a high-throughput
microarray approach, 11 genes (CDH3, CLDN5, FOXE1,
LHX1, NPTX2, RPRM, SFRP1, ST14, TJP2, UCHL1, and
WNT7A) markedly induced after treatment with 5-aza-
2-deoxycytidine (5Aza-dC), a DNA demethylation agent,
were specifically identified in pancreatic tumor cell lines
[63]. Analysis of the methylation status of these genes in
PTs showed that four genes (CLDN5, NPTX2, SFRP1,
UCHL1) were methylated in at least 93% of the screened
specimens, while only two (CDH3 and ST14) presented
methylation in less than 20% of samples.
A microarray-based method was used to interrogate
27,800 CGIs covering 21 Megabase-pairs of the human
genome. Then, 1968 CGIs showed differential methyla-
tion in pancreatic cancer cell lines compared to a
healthy pancreas. Validation in 57 PTs and 34 normal
pancreases confirmed specific methylation of MDFI,
MIR9-1, ZNF415, CNTNAP2, and ELOVL4 in cancer-de-
rived samples [64].
Further application of this strategy resulted in the
identification of > 1200 known loci that presenting spe-
cific methylation in PT. Many of these loci belonged to
Wnt signalling pathway or the homeobox and the cad-
herin superfamilies [61]. Analysis of 24 of these hyper-
methylated candidate genes (ADCY5, BMI1, BTBD6,
CACNA1H, EFNA4, FOXF2-G1, FZD1-2-7, HIC1, ID4,
IRF5, NEUROG3, PCDH17, PDE4B, SFRP1, SIM1,
SMOC2, SOX3-15, WNT3-5A, ZBTB16) was validated in
PT showing that for 20 genes DNA methylation was, on
average, 50% more frequent in PTs. Only for EFNA4,
BTBD6, and FZD2-7 DNA methylation levels were
comparable between the two conditions [61]. A tran-
scriptomics-based screening of pancreatic cell lines iden-
tified—from a pool of > 1400 genes—eight potential
biomarkers showing PT-specific DNA methylation
signatures [65]. This gene-panel was then used to probe
a large cohort of PT, CP, and healthy pancreas speci-
mens. The most frequently methylated genes in PTs
were BNC1 and ADAMTS1. Quantitative MSP (qMSP)
validation confirmed the results. Interestingly, BNC1
methylation was detected in PINs, while ADAMTS1
methylation was exclusively found in invasive PTs.
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Importantly, these two genes showed increased DNA
methylation in pre-neoplastic PINs, with little to no
DNA methylation in CP or healthy pancreas [65], thus
underlining their potential use for early PT diagnosis
and prognosis. In a comprehensive program, composed of
four case-control studies, PT-specific DNA-methylated
markers were further identified through NGS [22]. Ana-
lysis of > 1,000,000 CpG sites derived from matched PTs,
benign pancreas, and healthy colon tissue specimens re-
sulted in the identification of > 500 DNA-methylated re-
gions (DMRs). Interestingly, upon biological validation, six
of 87 candidate genes (CD1D, CLEC11A, IKZF1, KCNK12,
NDRG4, PRKCB) were further selected and tested as diag-
nostic biomarkers in cfDNA specimens (as described in
next section) [22].
NGS was also utilized to identify differentially DMRs
in healthy and neoplastic samples. Aberrantly methyl-
ated CGIs were more frequent in PT, compared to the
healthy pancreas, and DNA hypermethylation events in
PTs typically occurred in the vicinity of the transcription
start site (TSS). Several individual DMRs (including
C5orf38, DLX4, ELAVL2, EMX1, IRX1, NPR3, PITX2,
SIM2, TBX5, TFAP2C, and VSTM2B) were further vali-
dated by target-specific methods (MSP, direct bisulfite
sequencing or methylation-sensitive restriction endo-
nuclease PCR) [58]. It is well-known that DNA methyla-
tion can occur in diverse genomic contexts such as
promoters, CGIs and CGI shores, introns, exons, and
miRNAs. Epigenetic deregulation of non-coding genes
like microRNAs (miRs) is an established event in tumor
development. miRNA are commonly involved in inflam-
matory processes playing a role in coordinating several
features of the immune system, including immune cell
differentiation, function, and recruitment.
Three MIR124 genes and MIR10B showed a higher
mean CpG methylation fraction in PTs compared with
matched non-cancerous tissues. Hypermethylation in-
duced the silencing of MIR124, which was associated
with poor prognosis. The functional implications of such
findings derive from MIR124 role in inhibiting cell pro-
liferation, invasion, and metastasis. Among MIR124
direct targets, stem Rac1, a putative PT-promoting factor
that activates JNK-dependent cell motility [66–70].
Also, MIR210 and MIR130B displayed PT-specific
DNA-hypomethylation. Supporting evidence relates to
high levels of MIR210 to PT progression, epithelial-to-
mesenchymal transition, and adverse prognosis in cancer
patients [71, 72]. For MIR130B, its DNA methylation
levels [73] and the relative functional implications are
still controversial: while expression of MIR130B is
reported to inhibit cell proliferation and invasion in PTs
by direct targeting of STAT3 [74], increased levels of
this miR associates with the development of other neo-
plastic diseases [75].
Pancreatic cancer and pancreatitis cfDNA
methylation signatures in biological fluids
To find a diagnostic or prognostic tool relevant for PT,
several studies, rather than analyzing only one gene,
combined many candidate genes into aggregate bio-
markers. The methylation levels of the different genes in
the aggregate were adopted to differentially diagnose
pre-neoplastic conditions or PT from different biological
fluids, such as pancreatic juice and blood, as indicated in
Table 1.
While in PT solid biopsies, six methylated genes were
identified to be predictive of advanced disease; in pan-
creatic juice, only three of them (CLDN5, NPTX2, and
SFRP1) showed the potential to be employed as aggre-
gate biomarkers [63]. Indeed, aberrant DNA methylation
of at least one of the three was detectable in 75% of the
pancreatic juice specimens from PT and in none of the
benign samples. The absence of DNA methylation for all
three genes was observed in 16% of PTs, resulting in a
specificity of 75%. Of note, four PNETs were also probed
and displayed no DNA methylation. These results were
encouraging, and pancreatic juice from larger cohorts
was examined in other studies.
For example, Matsubayashi et al. investigated pancre-
atic juice endoscopically or surgically collected from
individuals with suspected pancreatic diseases, including
CP and benign pancreatic lesions [76]. Quantitative
interrogation of 17 target genes revealed increased DNA
methylation levels in all PT specimens (n = 56), com-
pared to the normal pancreas (n = 11). Further, the
number of methylated genes in the high-risk PT group
(n = 44) was more abundant than in healthy controls
but similar to patients with chronic pancreatitis (n = 11).
Combination of the five most discriminating assays
(CCND2, FOXE1, NPTX2, PENK, and TFPI2) scoring
DNA methylation in more than one gene was highly
predictive of PT: nine of 11 patients with PT but none
of the 64 individuals without detectable pancreatic neo-
plasia presented DNA methylation signal (82% sensitivity
and 100% specificity for PT). Interestingly, these genes
were previously identified in several studies conducted
on pancreatic biopsies. Although none of the target
genes was useful to distinguish CP from healthy pan-
creases, this aggregate biomarker successfully discrimi-
nated PTs from other pancreatic lesions.
In their clinical pilot testing, Kisiel et al. assessed the
DNA methylation levels of six previously identified
candidate biomarkers, together with mutant KRAS
status, on secretin-stimulated pancreatic juice samples
from 61 PT patients, 22 CP patients, and 19 with healthy
pancreas [22]. In line with previous findings, mutant
KRAS had a sensitivity of 56% and 39% (at 90% specifi-
city) in discriminating PTs or CP from healthy pan-
creases, respectively. Overall, the other biomarkers
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performed better: the sensitivity (at 90% specificity) in
discriminating PT from healthy pancreas was 79% for
CD1D, 67% for CLEC11A, 62% for IKZF1, 79% for
KCNK12, 72% for NDRG4, and 67% for PKRCB. The
sensitivity (at 90% specificity) in discriminating PT from
CP was generally lower: 53% for CLEC11A, 54% for
IKZF1, 46% for KCNK12, and 67% for NDRG4. Of note,
CD1D displayed a better discriminating potential be-
tween PT and CP (84%), while PKRCB methylation was
worse (38%) than mutant KRAS at distinguishing PTs
from CPs.
The collection of pancreatic juice is a relatively com-
plex procedure, and it might not be appropriate as a
standard approach for early detection in asymptomatic
individuals. For this, the analysis of cfDNA in plasma
specimens received increasing inputs.
Melnikov et al. examined plasma specimens of PT pa-
tients with a panel of 56 frequently methylated genes
[77]. By mean of a microarray-based approach [78], five
promoters were selected (CCND2, PLAU, SOCS1,
THBS1, and VHL) and combined in an aggregate bio-
marker. This test assesses DNA hypomethylation events,
which makes comparison with techniques that detect
cancer-related hypermethylation difficult. The assay dis-
tinguished healthy pancreas from PTs with 76% sensitiv-
ity and 59% specificity. Previous findings had reported
CCND2, SOCS1, and THBS1 hypermethylation as in-
formative for cancer detection in pancreatic juice or tis-
sues [52, 55, 79].
In a follow-up study by Liggett et al., 17 gene pro-
moters were examined to identify differential cfDNA
methylation in PT and CP patients [80]. Eight genes
(BRCA1, CCND2, CDKN1C, MLH1, proximal and distal
PGR promoter regions, SYK, and VHL) were useful to
distinguish healthy pancreas from CP, with a sensitivity
and a specificity of 82% and 78%, respectively. For all
genes in this panel, promoter DNA methylation was
more frequent in individuals with CP. Fourteen genes
(CCND2, CDKN1C, CDKN2B, DAPK1, promoter A of
ESR1, MGMT, MLH1, MUC2, MYOD1, PGK1, the
Table 1 List of cfDNA methylation aggregate biomarkers with high sensitivity for chronic pancreatitis or pancreatic cancer diagnosis
Aggregate biomarkers Comparison Diagnostic
method
Test performance (95% CI) Reference
Combined sensitivity Combined specificity
CLDN5 NPTX2 CP vs. PT MSP 75% 75% Sato et al. 2003a [59]
SFRP1
CCND2 FOXE1 N + CP vs. PT qMSP 82% 100% Matsubayashi et al. 2006 [76]
NPTX2 PENK
TFPI2
CCND2 PLAU N vs. PT MCAM 76% 59% Melnikov et al. 2009 [77]
SOCS1 THBS1
VHL
BRCA1 CCND2 N vs. CP MCAM 82% 78% Ligget et al. 2010 [80]
CDKN1C MLH1
PGR (distal) PGR (proximal)
SYK VHL
CDKN1C CDKN1B CP vs. PT MCAM 91% 91% Ligget et al. 2010 [80]
CCND2 DAPK1
ESR1(A) MGMT
MLH1 MUC2
MYOD1 PGK1
PGR (proximal) RARB
RB1 SYK
ADAMTS1 BNC1 N vs. PT qPCR 81% (69%–93%) 85% (71%–99%) Yi et al. 2013 [65]
APC BMP3 CP vs. PT MSP 76% 83% Henriksen et al. 2016 [82]
BNC1 MESTv2
RASSF1A SFRP1
SFRP2 TFPI2
Age (> 65)
CP chronic pancreatitis, PT pancreatic adenocarcinoma, N normal. The gene names’ was included in gene names’ abbreviation section
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proximal region of the PGR promoter, RARB, RB1, and
SYK) were able to distinguish CP from PTs with a sensi-
tivity and a specificity of 91%. It is worth noting that all
genes that were hypermethylated in CP displayed hypo-
methylation in PT. As CP often precedes PT, dynamic
DNA methylation patterns for a given set of genes might
underlie the progression of the disease. Validation in
larger independent cohorts would be critical to confirm
these findings.
Park et al. investigated the DNA methylation levels of
six genes (CDKN2A, NPTX2, PENK, SFRP1, RASSF1A,
and UCHL1) in the plasma of individuals with PT and
CP [81]. The investigated genes had previously been
reported to present high DNA methylation in 81% of
PTs (13 of 16 cases), 61% of CP (eight of 13 cases), with
more than one gene affected in either condition. In
contrast, less than 4% of healthy pancreases (one of 29)
presented DNA methylation. In this study, high interin-
dividual variability was observed, and significant differ-
ences between PT and CP could not be confirmed,
except for CDKN2A, specifically methylated in PT but
not in CP.
Scarcely abundant cfDNA is often a limiting factor for
many studies. To overcome such issue and improve the
sensitivity of DNA methylation detection, Yi et al.
employed a single-tube high-yield collection method,
termed methylation on beads (MOB) [65]. Based on
their previous screening, the authors determined the
sensitivity assuming that all patients with PT (stages I–
IV; n = 42) would harbor BNC1 and ADAMTS1 gene
methylation while healthy subjects (n = 26) would not
[65]. Further, 33 of 42 PT patients showed BNC1 methy-
lation, while 20 of 42 showed ADAMTS1 methylation,
with a sensitivity of 79% and 48% for BNC1 and
ADAMTS1, respectively. Specificity was 89% for BNC1
and 92% for ADAMTS1. Combining both genes slightly
improved the overall sensitivity (81%) but worsened the
overall specificity (85%).
A recent prospective study from Henriksen et al.
employed a panel of 28 genes to assess the DNA methyla-
tion state in patients with PT (n = 95), CP (n = 124), and
acute pancreatitis (n = 59) from plasma specimens [82].
Compared with CP, patients with PT presented more
methylated genes, on average (8.4 vs. 4.7). The authors de-
veloped a diagnostic prediction model that optimized the
combination of biomarkers to achieve the highest predict-
ive power. The model included eight genes (APC, BMP3,
BNC1, MESTv2, RASSF1A, TFPI2, and SFRP1-2) and pa-
tient’s age (> 65). Although not quantitative, this model
successfully distinguished malign from benign conditions
with a sensitivity of 76% and a specificity of 83%, inde-
pendently of the tumor stage.
Finally, a recent study by Lehmann-Werman et al. re-
vealed how cfDNA methylation patterns could be
employed to detect tissue-specific cell death in individ-
uals affected by PT or CP [21]. Array-based methylome
data from cadaveric material of different organs showed
that CUX2 and REG1A could be employed as pancreas-
specific markers. While the former was preferentially
unmethylated in ductal pancreatic cells, the latter was
found unmethylated in both acinar and ductal pancreatic
cells. cfDNA from matched plasma specimens showed
high levels of CUX2 and REG1A in individuals with late-
stage PT or CP. Levels of these markers were lower as
the grade of the lesion decreased, and it was minimum
in healthy individuals, leading to the conclusion that tis-
sue-specific cfDNA levels in the plasma directly reflect
cell death, irrespective of the etiology of the disease. Be-
sides, individuals affected by PT presented high levels of
the ductal-specific marker CUX2, whereas those affected
by CP had higher levels of the acinar-ductal marker
REG1A. In summary, hypomethylation of exocrine pan-
creas-specific cfDNA is detected in the blood of patients
with PT and CP, mirroring the death of exocrine cells in
these conditions.
cfDNA methylation as a diagnostic marker of pre-
neoplastic lesions
Liquid biopsies are convenient and minimally invasive if
compared to the more cumbersome and challenging pro-
cedure of tissue sampling. However, their utilization for
the development of cfDNA methylation biomarkers pre-
sents some pitfalls. Despite the high tissue specificity of
cfDNA methylation patterns [21] and the introduction of
high-yield collection methods [65], the scarce abundance
of disease-specific cfDNA remains a limiting factor. Thus,
to achieve robust data analysis, the investigation has to be
restricted to a few targets.
At present, what appears to be clear is that single
epigenetic markers are seldom sufficient to distinguish
pancreatic malign from benign or pre-neoplastic
conditions. The simultaneous evaluation of more bio-
markers has thus been investigated through systematic
approaches. Today, prediction models are extensively
used in a variety of biological fields [83, 84], and
models integrating the DNA methylation status of
target genes have been developed to provide prognos-
tic estimates for individuals with PT [85]. Similarly,
prediction models enabled the development of opti-
mized aggregate biomarkers that combined different
disease-specific informative targets, achieving high
predictive power [82]. These models successfully dis-
tinguished PT from non-neoplastic conditions or CP
with encouraging sensitivity and specificity. Besides,
the utilization of stratification (e.g., age) or prognostic
parameters may be a valid strategy to improve sensi-
tivity. Recent evidence indicates that aberrant DNA
methylation events correlate with longer patients’
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survival [73]. As can be seen from Table 1, which
shows the aggregate biomarkers discussed in this re-
view, the grouped genes analyzed by Ligget’s co-
workers represent an excellent combination of
sensitivity and specificity [80].
Figure 2 reports a schematic representation of the
genes that may provide DNA methylation stage-specific
information of pre-neoplastic conditions.
For some genes, DNA methylation may indeed mirror
different stages of the disease progression (e.g., ADAMTS1
or SOCS1, in PINs or IPMNs, respectively) [55, 56, 65].
Other genes show dynamic DNA methylation levels that
are increased by the persistent inflammatory environment
(e.g., CP) [57], yet they are unmethylated at advanced
stages of the disease (e.g., CCND2) [80]. On the other
hand, genes such as APC, BRCA1, CLDN5, LHX1, RPRM,
SFRP1, and TJP2, that progress to a state of increased
methylation in invasive cancer, can be considered bio-
markers of an aggressive stage of the disease [57, 63].
Conclusions
This review aimed to focus on the present advances in
liquid biopsy for PT to establish predictive aggregate
biomarkers that provide benefits to patients. Many
candidate genes have been discussed in this review, the
majority of which are hypermethylated as the pancreatic
disease progresses. Interestingly, the use of new tech-
nologies and array-based screening employed to analyze
DNA methylation status indicated that hypomethylation
events, rather than hypermethylation, could be more in-
formative because their occurrence appears to be inde-
pendent of the inner tumor heterogeneity [78]. Besides,
the decreasing cost of next-generation sequencing tech-
nologies offers an appealing option for methodological
standardization. In conclusion, early diagnosis has the
potential to allow prognosis prediction, tumor-stage
monitoring, and provide personalized therapeutic strat-
egies for patients suffering from a pancreatic disease.
Additional file
Additional file 1: Table S1. List of genes presenting differential DNA
methylation between healthy pancreas, chronic pancreatitis or pancreatic
cancer. CP: chronic pancreatitis; HiR: high PT-risk; IPMN: papillary
mucinous neoplasms; PIN: pancreatic intraepithelial neoplasias; PT:
pancreatic adenocarcinoma; PTX: pancreatic adenocarcinoma xenografts.
Hyper:DNA hypermethylation; hypo: DNA hypomethylation; –: no change;
inv.: invasive; *: non-significant; #: cohort size <10; §: p16INK4a specific
region; $: p14ARF specific region; £: associated with longer survival. Grey
Fig. 2 Epigenetic landscape of pancreatic cancer. Graphical representation of the genes presenting different DNA methylation levels in CP, pre-
neoplastic conditions, and invasive PT. Genes in bold present high DNA methylation levels, while normal formatting indicates that methylation is
detected, though at lower levels. Underline genes present controversial results (e.g., hypermethylation is reported by different studies). $:
p16INK4a specific region
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